34 results about "Choroid plexus" patented technology

A whole-body mathematical model (10) for simulating intracranial pressure dynamics. In one embodiment, model (10) includes 17 interacting compartments, of which nine lie entirely outside of intracranial vault (14). Compartments (F) and (T) are defined to distinguish ventricular from extraventricular CSF. The vasculature of the intracranial system within cranial vault (14) is also subdivided into five compartments (A, C, P, V, and S, respectively) representing the intracranial arteries, capillaries, choroid plexus, veins, and venous sinus. The body's extracranial systemic vasculature is divided into six compartments (I, J, O, Z, D, and X, respectively) representing the arteries, capillaries, and veins of the central body and the lower body. Compartments (G) and (B) include tissue and the associated interstitial fluid in the intracranial and lower regions. Compartment (Y) is a composite involving the tissues, organs, and pulmonary circulation of the central body and compartment (M) represents the external environment.

A novel ventricular catheter designed to reduce CSF shunt obstruction is disclosed comprising a tip using a membrane without any opening and capable of filtering the CSF. When the CSF flows through the membrane, neither tissue (choroid plexus, blood cells, tumor cells, suctioned ependymal tissue) nor proteins can break through the membrane, making this ventricular catheter capable of preventing obstruction from tissue invasion but also preventing clogging from protein precipitation, coagulation or flocculation along the downstream shunt system.

Compounds, compositions and methods are provided for modulating the expression of transthyretin in the brain, specifically the choroid plexus. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.

A device and system for flushing a shunt catheter utilizes the available cerebrospinal fluid (CSF) to flush a blocked catheter. The CSF is pressurized to a predetermined amount and then allowed to suddenly, rapidly and forcefully purge any occlusions. The rapid release of CSF produces flow jets from the catheter pores into the ventricle. This impulse, or “cough”, will push and divert choroid plexus and / or other blockages away from the pores. The device and system may then be allowed to refill at a slow rate, thus reducing the possibility of rapid suction of fluid back into the system and the attendant possibility of drawing the choroid plexus back into the pores. The catheter at the proximal end may also include back-up pores that can be opened to restart flow from the ventricle should the primary pores remain blocked after a flushing attempt.

Aspects of the present invention include methods and compositions related to the production and use of embryonic progenitor cell types useful in the generation of cartilage, bone, choroid plexus, tendon, lipasin-secreting adipocytes, and other differentiated cell types useful in research and therapy.

Compositions and methods are disclosed that relate to improved treatments for nervous system diseases and disorders using CNS-implanted semi-permeable biocompatible capsules containing encapsulated pathogen-free xenogeneic choroid plexus (CP) cells that are induced to produce altered (and in certain embodiments increased) levels of one or more cerebrospinal fluid (CSF) components. Capsules are selected as disclosed to be capable of induction of elevated CSF production levels by CP cells that are remarkably (>16 months post implant) long-lived, without eliciting immunological rejection, inflammation or foreign body response reactions.

A pluripotent stem cell isolated from the lateral ventrical of the brain or choroid plexus is provided. Compositions and methods of isolating and using the cell also is provided.

Aspects of the present invention include methods and compositions related to the production and use of embryonic progenitor cell types useful in the generation of cartilage, bone, choroid plexus, tendon, lipasin-secreting adipocytes, and other differentiated cell types useful in research and therapy.

The present invention is directed to the use of choroids plexus cells and / or choroids plexus conditioned media for enhancing the growth, survival and / or maintenance of function of non-choroid plexus cells grown in long term or short term culture.

The present invention is directed to the prevention or treatment of autoimmune diseases, and in particular, of type I diabetes, by administering a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.

The invention discloses a construction method and an application of a transgenic mouse with blood-brain barrier permeability enhanced. The construction method of the transgenic mouse with blood-brain barrier permeability enhanced comprises the step of modifying genes of a mouse, so that expression quantity of slit protein is increased, and a transgenic animal model with blood-brain barrier permeability enhanced is obtained; Study shows that overexpression of slit protein can cause that a tricorn of the mouse is enlarged, a choroid plexus structure is seriously destroyed, and tight junction of epithelium cells is lost; observation on a vascular structure of the brain of a Slit-Tg mouse by virtue of immunofluorescent staining shows that bifurcation of blood vessels of the brain of the Slit-Tg mouse is less, more microvessels exist, the shapes of vessels are incomplete and the distribution of the vessels is irregular; a transmission electron microscope map also shows that endothelial cells of the Slit-Tg mouse are damaged and highly irregular and basement membranes of vessels are incomplete. Evansblueassay detects that the permeability of the mouse is enhanced, i.e., the detection result shows that the blood-brain barrier permeability of the Slit-Tg mouse is enhanced, the Slit-Tg mouse can be applied to an animal experiment of central nervous system drugs and the Slit-Tg mouse can be used for screening, research and development as well as therapeutic effect evaluation on nervous system drugs.

The invention relates to a construction method of a PHB1 gene knockout non-human animal and application of the PHB1 gene knockout non-human animal in the fields of toxicology and biological medicine, the non-human animal is obtained by utilizing Cre / LoxP and CRISPR / Cas9 systems, PHB1 protein in venation plexus tissue of the non-human animal is not expressed or the expressed PHB1 protein does not have functions. The PHB1 gene knockout non-human animal can be used as an animal modle for screening medicines for obesity, diabetes, venation plexus related diseases, tumors or inflammations and researching the toxicity of heavy metals or other toxic substances on the venation plexus, and has important application value in research and development of medicines for obesity, diabetes, venation plexus related diseases, tumors or inflammations.

The invention relates to materials and methods for the modulation of intraocular and intracranial pressure, and treatment of associated conditions such as glaucoma and hydrocephalus. More specifically, the invention relates to adenoviral vectors of serotype ShH10, and their therapeutic use in transducing the CRISPR system into ciliary body or choroid plexus to modulate expression of aquaporin or carbonic anhydrase genes.

The present invention is directed to the use of choroid plexus cells and / or choroid plexus conditioned media for enhancing the growth, survival and / or maintenance of function of non-choroid plexus cells grown in long term or short term culture.

Methods and materials relating to cultured choroid plexus organoids comprising: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by an epithelium, plus other authentic features and markers.

A nucleic acid construct and construct system are disclosed. The nucleic acid construct and system comprise a regulatory sequence which regulates inducible expression of a polypeptide of interest, the regulatory sequence comprising a choroid plexus specific promoter, with the proviso that the choroid plexus specific promoter is not a transthyretin promoter. Pharmaceutical compositions comprising same and uses thereof are also disclosed.

A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided.

The invention discloses an application of an amino acid composition to a medicine for treating fetal nervous system development diseases, including a pharmaceutical application of the amino acid composition. The amino acid composition is used for preparing the medicine composition for preventing and treating the fetal nervous system development diseases. The invention further discloses an amino acid composition identification and statistical processing method. Amino acid metabolism characteristics of fetal amniotic fluid with abnormal central nervous system isolated soft indexes obtained by ultrasonic guided amniotic cavity puncture are studied to obtain the pharmaceutical composition for preventing and treating fetal nervous system development diseases, so that the diseases of simple ventricular plexus cyst and simple lateral ventricular dilatation of a fetus are treated, and the development and perfection of a fetal cranial nervous system are promoted.

The invention relates to the fields of medicines, health-care foods and foods, and concretely relates to application of a compound in the preparation of a medicine with the function of improving collateral plexus. The compound is shown as a formula (I), can recover normal tissue structures and physiological functions of venation plexus, can also regulate secretion of cerebrospinal fluid, and has a better application effect in the aspect of preparing medicines with the effect of improving the venation plexus.

The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and / or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and / or the New World arenaviruses such as Junin virus, and / or a medicament comprising the compound.An arenavirus proliferation inhibitor comprising a compound represented by Formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof:(wherein R1 is carboxy, or the like; A3 is CR2 or N; R2 is a hydrogen atom, halogen, hydroxy, or the like; R3 is a hydrogen atom, hydroxy, carboxy, cyano, formyl, alkyl optionally substituted with Substituent group F, or the like; either A1 or A2 is CR6R6, and the other is NR7, or A1 is CR8R9, and A2 is CR10R11; and R5, R6, R7, R8, R9, R10, and R11 are each independently a hydrogen atom, carboxy, cyano, alkyl optionally substituted with Substituent group F, or the like).

The invention discloses a ventricular puncture model and belongs to the field of medical teaching instruments. The ventricular puncture model is characterized by comprising a skull model, a brain model and a thrombus model; a skull is divided into an upper skull structure and a lower skull structure from the temporal part; a detachable component is arranged between the upper skull structure and the lower skull structure; holes are formed in the left and right sides of the top of the upper skull structure of the skull; a brain model comprises left and right ventricle models and a third ventricle model; the third ventricle model is arranged in the left ventricle model and the right ventricle model; the surface of the brain model is provided with grooves; venation plexus is arranged in the brain model; a specific hydrogel material is adopted, so that the touch feeling is simulated; key brain structures such as left and right ventricles and a third ventricle in an intracranial hyperbaric state are included, and important brain characteristics such as cerebral gullet, venation plexus and the like are contained; and through the design of the auxiliary fixing device and the cerebral groove position, the model can be repeatedly used for brain puncture operations such as third ventricular fistulization and cerebral hematoma aspiration, and the teaching experiment effect can be greatly improved.

The invention relates to a method for constructing a PHB1 gene knockout non-human animal and its application in the fields of toxicology and biomedicine. The non-human animal is obtained by using the Cre / LoxP and CRISPR / Cas9 system, and PHB1 is contained in the choroid plexus of the non-human animal. The protein does not express or the expressed PHB1 protein has no function, and can be used as an animal model for obesity, diabetes, choroid plexus-related diseases, tumor or inflammation drug screening and heavy metal or other toxic substances on the choroid plexus toxicology research. Obesity, diabetes, choroid plexus The research and development of plexus-related diseases, tumors or inflammation drugs has important application value.

Methods of using serum glucocorticoid induced kinase 1 (SGK1) inhibitors for reducing the development of diseases related to salt and water balance, and in particular, hydrocephalus and / or hypertension, are disclosed herein. Particularly, the present disclosure is directed to the use of SGK1 inhibitors to inhibit transepithelial ion transport, such as in one embodiment, in the choroid plexus of a subject, thereby reducing cerebrospinal fluid (CSF) production or, alternatively, in another embodiment, to inhibit transepithelial sodium transport in the kidney collecting duct thereby reducing sodium reabsorption into the blood.